GlassScriptPhysician profile
Kimberly Wallach
NPI 1710609631
$1,925.75
in general payments reported to CMS, 2019-2025
21 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $478 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $534.34 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Novo Nordisk INC | $357.78 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Alexion Pharmaceuticals, INC. | $190.15 | 2024-2025 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $114.68 | 2024-2025 | |
| Lilly USA, LLC | $90.06 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Insulet Corporation | $85.48 | 2024-2025 | Omnipod |
| Amgen INC. | $83.68 | 2025 | Tepezza |
| Medtronic, INC. | $71.54 | 2024-2025 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $51.00 | 2025 | Yorvipath |
| Cequr Corporation | $49.56 | 2024-2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.15 | 2025 | Jardiance |
| Abbvie INC. | $36.43 | 2025 | |
| Tolmar, INC. | $34.82 | 2025 | Jatenzo |
| Ibsa Pharma INC. | $33.16 | 2025 | Flector, Licart, Tirosint |
| Amneal Pharmaceuticals LLC | $26.77 | 2025 | Unithroid |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $26.36 | 2025 | Qutenza |
| Tandem Diabetes Care, INC. | $23.12 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $22.18 | 2025 | Twiist |
| Sanofi-Aventis U.S. LLC | $19.88 | 2025 | |
| Almatica Pharma LLC | $17.40 | 2025 | Teriparatide |
| Amphastar Pharmaceuticals, INC. | $14.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Wallach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.